Biogen Idec, Inc. (Massachusetts) Gets Letter Of Deficiency From Health Canada On Fampridine

Dow Jones -- Biogen Idec Inc. (BIIB) has received a letter of deficiency from Health Canada for its application to sell the multiple sclerosis treatment fampridine in the country.